Medical Services

Clinical Trials at Englewood Hospital: Oncology

- Please scroll down to view all studies -

Kidney Cancer

EHMC IRB Study #: E-13-530

Principal Investigator:
Dr. Brian Kim
Tel: 201-894-3533
Email: bkim@fsahemonc.com

Study Coordinator:
Audrey Ades
Tel: 201-894-3603
Email: audrey.ades@ehmc.com

Sponsor:
Alliance

Study Title:
A031203: Randomized Phase II Study Comparing Cabozanitinib with Commercially Supplied Sunitinib in Patients with Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma

Eligibility requirements:
Patients who are at least 18 years old with untreated advanced or metastatic kidney cancer.

Study objectives:
To determine if patients with renal cancer treated with cabozanitinib will have improved progression-free survival compared to patients treated with sunitinib.

Summary of procedures:
Eligible patients are randomized 1:1 to receive either cabozanitinib or sunitinib in 6-week cycles. Both drugs are pills taken by mouth. Treatment will continue until disease progression, intolerable side effects, or withdrawal of consent. Subjects will be followed every 12 weeks until disease progression and then every 6 months until 5 years after registration.

###

EHMC IRB Study #: E-11-423

Principal Investigator:
Dr. Brian Kim
Tel: 201-894-3533
Email: bkim@fsahemonc.com

Study Coordinator:
Audrey Ades
Tel: 201-894-3603
Email: audrey.ades@ehmc.com

Sponsor:
National Cancer Institute - SWOG

Study Title:
EVEREST: Everolimus for Renal Cancer Ensuing Surgical Thearpy, a Phase III Study

Eligibility requirements:
Patients who are at least 18 years old with confirmed renal cell carcinoma, who have undergone a full resection with negative margins, and who have not received any prior treatment.

Study objectives:
To compare recurrence-free survival in renal carcinoma patients randomly assigned to one year of everolimus vs. one year of placebo after nephrectomy or partial nephrectomy.

Summary of procedures:
Patients will be randomized to receive either everolimus or placebo daily by mouth for nine, six-week cycles.  Assessments for recurrence will be done every three cycles (18 weeks) for 54 weeks, then every 6 months for two years, then annually thereafter until recurrence Year 10, whichever occurs first.

 

Clinical Trials Research Center
Active Clinical Trials
Oncology
Resources for EHMC Physicians
Research Developments - Newsletter